DUBLIN – Cytos Biotechnology AG out-licensed all oncology applications of its immuno-stimulatory therapeutic vaccine CYT003 and its underlying phage Qbeta-based virus-like particle (VLP) technology to start-up cancer immunotherapy firm Checkmate Pharmaceuticals Inc., in a deal worth up to $90 million in milestones plus double-digit royalties on eventual product sales.